Popular Articles

Pharmacy Union Concerns Unfounded
Concerns raised by the Pharmacists" Division of the Association of Professional
generic viagra online
Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus" proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, polymerization, or encapsulation and enables administration through a fine gauge needle. The Phase 2 ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the U.S. and targets enrolling 36 growth hormone deficient pediatric patients. ALTU-238 has been studied in a series of Phase 1 and Phase 2 studies in healthy and GH deficiency adults.
News of the day
Boston Scientific Announces European Approval For Its Latitude(R) Patient Management System
Boston Scientific Corporation (NYSE: BSX) announced CE Mark for its LATITUDE® Patient Management system. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient"s heart health status. The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient"s physician. It will be launched in Europe in a phased approach beginning this week.
Sexual Health

USC Researchers Uncover Mechanism That Allows Influenza Virus To Evade The BodyÂðs Immune Response

California (USC) have identified a critical molecular mechanism that allows the influenza virus to evade the bodyÂðs immune response system. The study will be published in the May 21 issue of the journal Cell Host & Microbe. ÂöWe have found a mechanism that the influenza virus uses to inhibit the bodyÂðs immune response that emphasizes the vital role of a specific protein in defending against viruses," says Jae Jung, Ph.D., professor and chair of the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC, and the principal investigator of the study. ÂöAlong with our previous studies (Nature 2007 and PNAS 2008), this finding could provide researchers with the information needed to create a new drug to enhance immunity and block influenza virus infection and replication." Several specific intracellular receptors are responsible for detecting the virus and activating the bodyÂðs defensive mechanisms. When a virus" RNA enters the intracellular fluid, a receptor known as retinoic-acid-inducible gene I (RIG-I) detects it and triggers a response that limits virus replication and calls the bodyÂðs defenses into action. RIG-I acts as the sensor and security force against attacks, Jung explains. Then, a protein known as TRIM25 helps RIG-I transmit an alarm signal, which ultimately floods the cell and surrounding tissue with antiviral interferons. The influenza virus is highly infectious and poses a serious and sometimes deadly health risk because of its ability to mutate into new strains and spread quickly during seasonal epidemics, as seen in the recent outbreak of the H1N1 swine flu virus, Jung says. Researchers have long been working to understand how respiratory influenza is able to slip past the bodyÂðs innate immune responses. They have found that the influenza A virus has evolved by incorporating Non-structural protein 1 (NS1) into its genome to escape the RIG-I alarm system. This process is one reason why the virus kills an average of 36,000 people every year. In fact, the 1918 "Spanish flu" pandemic influenza virus, which killed over 40 million people worldwide, muted the RIG-I response and interferon activity much more efficiently than contemporary flu viruses, Jung notes. "Despite the conceptual linking of RIG-I with flu virus NS1, however, the precise mechanism has been unclear for a long period of time," he says. By studying the immune responses of animal models, researchers found that the influenza A virus NS1 attacks TRIM25, inhibiting its ability to assist RIG-I trigger the alarm system against the virus. Remarkably, a flu virus carrying an NS1 mutant defective for this activity loses its virulence in animal models, Jung says. "We now know that the influenza virus escapes recognition via the interaction of NS1 with TRIM25, which inhibits the bodyÂðs immune response," he says. ÂöUnderstanding this host-virus interaction is an essential step in developing safe and effective drugs to target the influenza virus.² This work was performed in collaboration with Adolfo Garcia-Sastre, Ph.D., at Mt. Sinai Medical School and the final doctorate experiments of Michaela Gack, Ph.D., who is the paperÂðs first author and currently a faculty member at Harvard Medical School. "Influenza A Virus NS1 Targets the Ubiquitin Ligase TRIM25 to Evade Recognition by the Host VIral RNA Sensor RIG-I." Michaela Ulrike Gack, Randy Allen Albrecht, Tomohiko Urano, Kyung-Soo Inn, I-Chueh Huang, Elena Carnero, Michael Farzan, Satoshi Inoue, Jae Ung Jung*, Adolfo Garica-Sastre*. Cell Host & Microbe. DOI: 10.1016/j.chom.2009.04.006. USC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):